The relationship between antidepressant and suicide risk is one of the topics of medical research. Studies have found an association between some antidepressants and an increased risk of suicide. This problem has now become so important that in some places government intervention has been labeled as a higher risk of suicide due to the use of antidepressants. Exactly what causes this is not yet clear, but other studies have shown that antidepressants prevent suicidal thoughts.





High levels of risk for young people:


People under the age of 24 who suffer from travel depression are warned that antidepressants can increase the risk of suicidal thoughts and behaviors. Federal health officials announced in December 2008 a change in the drug's antidepressant label to warn users of the dangers.



The FDA prohibits children and adolescents suffering from depression from using pixels and projectors.



Prescribing SSRIs (selective serotonin reuptake inhibitors) to children and adolescents has been reduced after the United States and European regulatory agencies warned of the potential suicide risk of antidepressants for pediatric patients. The decline in drug prescriptions was associated with an increase in child and adolescent suicide rates of 14% and 50%, respectively, in the United States and the Netherlands.

Recommended Reading: Reversal: The Secret Thinking Skill


A review was conducted in 2016 of 70 clinical trials with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), with 16,500 participants. Through these individuals and clinical reports and data obtained, four outcomes are explored - death, suicidal tendencies, aggressive behavior, and agitation. As can be seen from this, it is not possible to draw strong conclusions about these four issues from the data obtained. Adults taking the drug were not found to have a higher risk in these four cases, but in children, the risk of suicide and aggression was doubled. The authors of the review report expressed incomplete reporting and a lack of additional data and frustration. There was also some frustration among them about setting up clinical trials. [1]

Caution:

According to Food and Drug Administration (FDA) guidelines, all SSRI drugs will have "black box warnings" on them, doubling the risk of suicide in children and adolescents (2 to 1 in 1,000). , 4 out of 1,000. [2] It is still disputed whether this increased suicide risk is due to medication (a paradoxical effect) or to depression (i.e., those who suffer from severe depression (those who are naturally paralyzed or paralyzed due to depression). Antidepressants enable them to be more alert and create a suicidal tendency to completely recover from their depressive episodes). [3]



A 2009 study found that taking antidepressants depended on age for suicidal tendencies and behaviors and only the risk of suicidal behaviors. Studies have shown that suicidal tendencies or behaviors (in which case any of these can occur) and the odd ratio of suicidal behaviors alone are 1.82 and 2.3, respectively, for persons under 25 years of age; It is 0.89 and 0.8 for people between the ages of 25 and 65, and 0.38 and 0.08 for those over 65, respectively. From this it can be deduced that the risk is much higher in people under 25 years of age, the risk is relatively low in people between 25 and 65 years of age and the risk is much lower in people over 65 years of age. It also shows that the ad ratio for suicidal thoughts or behaviors decreases by 2.6% per year, and the ad ratio for suicidal behaviors alone decreases by 4.8% per year. [4]

In the case of young patients, especially in the first eight weeks of receiving therapy, it is important to observe very carefully and to see if there are any signs of suicidal thoughts or suicidal behavior. Sertraline, tricyclic agents, and venlafaxine have been shown to increase suicidal tendencies in adolescents with severe depression. [5]

There is a greater risk of stopping treatment:

A 2009 study found that medical initiatives (starting new medications), titration (increasing or decreasing doses if desired results were not obtained), and discontinuation (discontinuation) increased the risk of suicide. [6] 159, A study of 610 users of amitriptyline, fluoxetine, paroxetine, or dothiepin found that these antidepressants were taken in the first 1 to 3 months of life, especially in the first month of pregnancy. Increases. [6]

Outbreak Of Suicide:

On September 6, 2007, the Centers for Disease Control and Prevention reported that adolescents in the United States (especially girls between the ages of 10 and 24) had the highest suicide rate in 15 years from 2003 to 2004, at 6 percent. [6] While the number of suicides among 10- to 24-year-olds was 4,232 in 2003, it rose to 4,599 in 2004, bringing the suicide rate to 8.32 per lakh. Earlier, the number of suicides per article dropped from 9.46 in 1990 to 6.8 in 2003. John Juraidini, a critic of the study, compared the 2004 suicide rate in the United States statistically to previous years but did not take into account the changes that have taken place over the years. "[9] According to the new epidemiological data, the suicide rate in 2005 decreased despite the reduction in the prescription of SSRI drugs. "It is risky to draw any conclusions from a limited ecological analysis of antidepressant prescriptions and suicide commas as a separate year." [10]

A credible pathological effort examines the relationship between psychotropic treatment and suicide. Data is collected from small geographical areas over a long period. It is prudent not to comment on the FDA's caution on public health responses until a detailed analysis is available. [11] [12] Subsequent follow-up studies have shown that antidepressant drugs reduce the risk of suicide. Supported. [13] [14]

Antidepressants reduce the risk of suicide:

A 2012 study from data from 41 clinical trials involving more than 9,000 patients concluded, “Fluoxetine and venlafaxine reduce suicidal thoughts and behaviors between adult and general patients. In this case, as a result of the treatment, the symptoms of depression are reduced and the suicidal thoughts and behaviors are reduced. In young people, no effect of these drugs on suicidal thoughts and behavior have been observed, although treatment has been shown to reduce depression. There was no evidence of increased suicide risk among young people receiving active treatment. "[15]

References:


  2. "Antidepressants double suicidality in children, says FDA"। BMJ। 332 (7542): 626। DOI:10.1136/bmj.332.7542.626-c
  3.  "SSRI Antidepressants"। Patient.info।
  4.  Stone, M.; Laughren, T.; Jones, M L.; Levenson, M.; Holland, P C.; Hughes, A.; Hammad, T. A; Temple, R.; Rochester, G. (2009)। "Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration"
  6. Valuck, Robert J.; Orton, Heather D.; Libby, Anne M. (2009)। "Antidepressant Discontinuation and Risk of Suicide Attempt"। The Journal of Clinical Psychiatry। 70 (8): 1069–77। DOI:10.4088/JCP.08m04943। PMID 19758520

  7. Jick, H.; Kaye, JA; Jick, SS (2004)। "Antidepressants and the Risk of Suicidal Behaviors"। JAMA। 292 (3): 338–43। DOI:10.1001/jama.292.3.338। PMID 15265848
  8. Carey, Benedict (2007)। "Suicide Rises in Youth; Antidepressant Debate Looms"। New York Times।

  9. Jureidini, J. (2007)। "The Black Box Warning: Decreased Prescriptions and Increased Youth Suicide?"। American Journal of Psychiatry। 164 (12): 1907; author reply 1908–10। DOI:10.1176/appi.ajp.2007.07091463। PMID 18056248
  11. Olfson, M.; Shaffer, D. (2007)। "SSRI Prescriptions and the Rate of Suicide"। American Journal of Psychiatry। 164 (12): 1907–1908। DOI:10.1176/appi.ajp.2007.07091467। PMID 18056247
  13. Bridge, Jeffrey A.; Iyengar, S; Salary, CB; Barbe, RP; Birmaher, B; Pincus, HA; Ren, L; Brent, DA (2007)। "Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials"। JAMA। 297(15): 1683–96। DOI:10.1001/jama.297.15.1683। PMID 17440145

  14.  Beasley, Charles M.; Ball, Susan G.; Nilsson, Mary E.; Polzer, John; Tauscher-Wisniewski, Sitra; Plewes, John; Acharya, Nayan (2007)। "Fluoxetine and Adult Suicidality Revisited"। Journal of Clinical Psychopharmacology। 27 (6): 682–6। DOI:10.1097/jcp.0b013e31815abf21। PMID 18004137
  15.  Gibbons, Robert D.; Brown, C. Hendricks; Hur, Kwan; Davis, John M.; Mann, J. John (2012)। "Suicidal Thoughts and Behavior with Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled Studies of Fluoxetine and Venlafaxine"। Archives of General Psychiatry। 69 (6): 580–7। DOI:10.1001/archgenpsychiatry.2011.2048। PMID 22309973


Depression And Suicide Risk
Suicide and Depression Risks